Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05855005 · ClinicalTrials.gov registry record · NA

Direct-to-Consumer Hearing Aids and Listening Effort

A NA study, sponsored by Northwestern University.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT05855005: Completed NA study, sponsored by Northwestern University.

NCT05855005 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05855005, a NA study, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

The aim of this proposed project is to understand whether direct to consumer (DTC) hearing aids programmed to individual hearing losses, can reduce listening effort for effective communication. If DTC aids can provide benefits beyond amplification, then they could be an affordable option to reduce barriers to care and improve hearing aid uptake in adults with hearing loss.

Primary Outcome

Participant and their communication partner discuss pictures with slight differences and attempt to locate all the differences by discussion alone. Primary measurement is average time for each correctly identified difference. A decrease in time indicates improved efficiency in the task.

Interventions

  • DEVICE DTC Hearing Aids

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-10-25
Est. Completion 2023-12-30
Phase NA
Northwestern University

1,209 total trials

What the finished NCT05855005 record still lists

NCT05855005 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which DTC Hearing Aids is the first listed.

NCT05855005 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05855005 about?

NCT05855005 is a clinical study titled "Direct-to-Consumer Hearing Aids and Listening Effort". The aim of this proposed project is to understand whether direct to consumer (DTC) hearing aids programmed to individual hearing losses, can reduce listening effort for effective communication. If DTC aids can provide benefits beyond amplification, then they could be an affordable option to reduce b...

What is the current status of trial NCT05855005?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-10-25. Estimated completion is 2023-12-30.

What interventions are being tested in trial NCT05855005?

The interventions under investigation include: DTC Hearing Aids (DEVICE).

Who is sponsoring clinical trial NCT05855005?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05855005's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05855005, the US trial registry maintained by the National Library of Medicine. NCT05855005 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.